Is RAS blockade routinely indicated in hypertensive kidney transplant patients?

Current Hypertension Reports

Volumn 9, Issue 5, 2007, Pages 422-429

  Salzberg, Daniel J ^a  

^a UNIVERSITY OF MARYLAND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 ETHYL 5,7 DIMETHYL 3 [4 [2 (2H TETRAZOL 5 YL)PHENYL]BENZYL]IMIDAZO[4,5 B]PYRIDINE; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCINEURIN INHIBITOR; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CILAZAPRIL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; LISINOPRIL; LOSARTAN; NIFEDIPINE; PLACEBO; QUINAPRIL; RAPAMYCIN; RENIN INHIBITOR; STEROID; TACROLIMUS; VALSARTAN;

ACUTE GRAFT REJECTION; ANEMIA; ANTIGEN ANTIBODY REACTION; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CHRONIC GRAFT REJECTION; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG CHOICE; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG USE; FIBROSING ALVEOLITIS; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT SURVIVAL; HEART LEFT VENTRICLE HYPERTROPHY; HUMAN; HYPERKALEMIA; HYPERTENSION; INCIDENCE; KIDNEY ALLOGRAFT; KIDNEY ARTERY STENOSIS; KIDNEY FAILURE; KIDNEY GRAFT REJECTION; KIDNEY INJURY; KIDNEY TRANSPLANTATION; MORTALITY; NEPHROTOXICITY; NONHUMAN; PATHOGENESIS; PREVALENCE; PROTEINURIA; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK ASSESSMENT; RISK FACTOR; SIDE EFFECT; SURVIVAL RATE;

ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; GRAFT SURVIVAL; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; KIDNEY TRANSPLANTATION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RENIN-ANGIOTENSIN SYSTEM;

EID: 36849003353     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-007-0077-4     Document Type: Review

References (55)

1. Peeters J, Roels L, Vanrenterghem Y: Chronic renal allograft failure: clinical overview. The Leuven Collaborative Group for Transplantation. Kidney Int Suppl 1995, 52:S97-101.
2. Artz MA, Hilbrands LB, Borm G, et al.: Blockade of the renin-angiotensin system increases graft survival in patients with chronic allograft nephropathy. Nephrol Dial Transplant 2004, 19:2852-2857.
3. Raine AE: Does antihypertensive therapy modify chronic allograft failure? Kidney Int Suppl 1995, 52:S107-111.
4. Kasiske BL, Anjum S, Shah R, et al.: Hypertension after kidney transplantation. Am J Kidney Dis 2004, 43:1071-1081.
5. Sorof JM, Sullivan EK, Tejani A, Portman RJ: Antihypertensive medication and renal allograft failure: a North American Pediatric Renal Transplant Cooperative Study report. J Am Soc Nephrol 1999, 10:1324-1330.
6. Sanders CE Jr, Curtis JJ: Role of hypertension in chronic renal allograft dysfunction. Kidney Int Suppl 1995, 52:S43-47.
7. Oliveras A, Vazquez S, Hurtado S, et al.: Ambulatory blood pressure monitoring in renal transplant patients: modifiable parameters after active antihypertensive treatment. Transplant Proc 2004, 36:1352-1354.
8. Budde K, Waiser J, Fritsche L, et al.: Hypertension in patients after renal transplantation. Transplant Proc 1997, 29:209-211.
9. Lipkin GW, Tucker B, Giles M, Raine AE: Ambulatory blood pressure and left ventricular mass in cyclosporin- and non-cyclosporin-treated renal transplant recipients. J Hypertens 1993, 11:439-442.
10. McNally PG, Feehally J: Pathophysiology of cyclosporin A nephrotoxicity: experimental and clinical observations. Nephrol Dial Transplant 1992, 7:791-804.
11. Bruno S, Remuzzi G, Ruggenenti P: Transplant renal artery stenosis. J Am Soc Nephrol 2004, 15:134-141.
12. Conte G, Dal Canton A, Sabbatini M, et al.: Acute cyclosporine renal dysfunction reversed by dopamine infusion in healthy subjects. Kidney Int 1989, 36:1086-1092.
13. Lee DB: Cyclosporine and the renin-angiotensin axis. Kidney Int 1997, 52:248-260.
14. Khanna A, Kapur S, Sharma V, et al.: In vivo hyperexpression of transforming growth factor-beta1 in mice: stimulation by cyclosporine. Transplantation 1997, 63:1037-1039.
15. Little DM, Haynes LD, Alam T, et al.: Does transforming growth factor beta 1 play a role in the pathogenesis of chronic allograft rejection? Transplant Int 1999, 12:393-401.
16. Crowley SD, Tharaux PL, Audoly LP, Coffman TM: Exploring type I angiotensin (AT1) receptor functions through gene targeting. Acta Physiol Scand 2004, 181:561-570.
17. Cosio FG, Pelletier RP, Pesavento TE, et al.: Elevated blood pressure predicts the risk of acute rejection in renal allograft recipients. Kidney Int 2001, 59:1158-1164.
18. Cosio FG, Pelletier RP, Sedmak DD, et al.: Renal allograft survival following acute rejection correlates with blood pressure levels and histopathology. Kidney Int 1999, 56:1912-1919.
19. Opelz G, Wujciak T, Ritz E: Association of chronic kidney graft failure with recipient blood pressure. Collaborative Transplant Study. Kidney Int 1998, 53:217-222.
20. Mange KC, Cizman B, Joffe M, Feldman HI: Arterial hypertension and renal allograft survival. JAMA 2000, 283:633-638.
21. Mimran A, Ribstein J: Angiotensin-converting enzyme inhibitors versus calcium antagonists in the progression of renal diseases. Am J Hypertens 1994, 7(9 Pt 2):73S-81S.
22. Tutone VK, Mark PB, Stewart GA, et al.: Hypertension, antihypertensive agents and outcomes following renal transplantation. Clin Transplant 2005, 19:181-192.
23. Ruggenenti P, Perico N, Mosconi L, et al.: Calcium channel blockers protect transplant patients from cyclosporine-induced daily renal hypoperfusion. Kidney Int 1993, 43:706-711.
24. Vlahakos DV, Canzanello VJ, Madaio MP, Madias NE: Enalapril-associated anemia in renal transplant recipients treated for hypertension. Am J Kidney Dis 1991, 17:199-205.
25. Curtis JJ, Luke RG, Whelchel JD, et al.: Inhibition of angiotensin-converting enzyme in renal-transplant recipients with hypertension. N Engl J Med 1983, 308:377-381.
26. Andrés A, Morales E, Morales JM, et al.: Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study. Transplant Proc 2006, 38:2419-2423.
27. Kornerup HJ, Pedersen EB, Fjeldborg O: Kidney transplant artery stenosis. Interrelationship between blood pressure, kidney function, renin-aldosterone system and body sodium content. Proc Eur Dial Transplant Assoc 1977, 14:377-385.
28. del Castillo D, Campistol JM, Guirado L, et al.: Efficacy and safety of losartan in the treatment of hypertension in renal transplant recipients. Kidney Int Suppl 1998, 68: S135-139.
29. Curtis JJ, Laskow DA, Jones PA, et al.: Captopril-induced fall in glomerular filtration rate in cyclosporine-treated hypertensive patients. J Am Soc Nephrol 1993, 3:1570-1574.
30. Shihab FS, Bennett WM, Tanner AM, Andoh TF: Angiotensin II blockade decreases TGF-beta1 and matrix proteins in cyclosporine nephropathy. Kidney Int 1997, 52:660-673.
31. Dragun D, Muller DN, Brasen JH, et al.: Angiotensin II type 1-receptor activating antibodies in renal-allograft rejection. N Engl J Med 2005, 352:558-569.
32. Calvino J, Lens XM, Romero R, Sanchez-Guisande D: Long-term anti-proteinuric effect of losartan in renal transplant recipients treated for hypertension. Nephrol Dial Transplant 2000, 15:82-86.
33. Lewis EJ, Hunsicker LG, Clarke WR, et al.: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345:851-860.
34. Bochicchio T, Sandoval G, Ron O, et al.: Fosinopril prevents hyperfiltration and decreases proteinuria in post-transplant hypertensives. Kidney Int 1990, 38:873-879.
35. Mason J, Muller-Schweinitzer E, Dupont M, et al.: Cyclosporine and the renin-angiotensin system. Kidney Int Suppl 1991, 32:S28-32.
36. Border WA, Noble NA: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998, 31(1 Pt 2):181-188.
37. Kagami S, Kuhara T, Okada K, et al.: Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells. Kidney Int 1997, 51:664-671.
38. Shihab FS, Tanner AM, Shao Y, Weffer MI: Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection. Kidney Int 1996, 50:1904-1913.
39. Sharma K, Eltayeb BO, McGowan TA, et al.: Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999, 34:818-823. [Published erratum appears in Am J Kidney Dis 2000, 35:572.]
40. Campistol JM, Inigo P, Jimenez W, et al.: Losartan decreases plasma levels of TGF-beta1 in transplant patients with chronic allograft nephropathy. Kidney Int 1999, 56:714-719.
41. Lindholm LH, Ibsen H, Dahlof B, et al.: Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet 2002, 359:1004-1010.
42. Yusuf S, Sleight P, Pogue J, et al.: Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigators. N Engl J Med 1992, 327:685-691.
43. Heinze G, Mitterbauer C, Regele H, et al.: Angiotensin-converting enzyme inhibitor or angiotensin II type 1 receptor antagonist therapy is associated with prolonged patient and graft survival after renal transplantation. J Am Soc Nephrol 2006, 17:889-899.
44. Hausberg M, Barenbrock M, Hohage H, et al.: ACE inhibitor versus beta-blocker for the treatment of hypertension in renal allograft recipients. Hypertension 1999, 33:862-868.
45. Midtvedt K, Hartmann A, Foss A, et al.: Sustained improvement of renal graft function for two years in hypertensive renal transplant recipients treated with nifedipine as compared to lisinopril. Transplantation 2001, 72:1787-1792.
46. Hadjigavriel M, Kyriakides G: Efficacy and safety of losartan in renal transplant recipients. Transplant Proc 1999, 31:3300-3301.
47. Premasathian NC, Muehrer R, Brazy PC, et al.: Blood pressure control in kidney transplantation: therapeutic implications. J Hum Hypertens 2004, 18:871-877.
48. Lorenz M, Billensteiner E, Bodingbauer M, et al.: The effect of ACE inhibitor and angiotensin II blocker therapy on early posttransplant kidney graft function. Am J Kidney Dis 2004, 43:1065-1070.
49. Heinze G, Collins S, Benedict MA, et al.: The association between angiotensin converting enzyme inhibitor or angiotensin receptor blocker use during postischemic acute transplant failure and renal allograft survival. Transplantation 2006, 82:1441-1448.
50. Traindl O, Falger S, Reading S, et al.: The effects of lisinopril on renal function in proteinuric renal transplant recipients. Transplantation 1993, 55:1309-1313.
51. el-Agroudy AE, Hassan NA, Foda MA, et al.: Effect of angiotensin II receptor blocker on plasma levels of TGF-beta 1 and interstitial fibrosis in hypertensive kidney transplant patients. Am J Nephrol 2003, 23:300-306.
52. Amuchastegui SC, Azzollini N, Mister M, et al.: Chronic allograft nephropathy in the rat is improved by angiotensin II receptor blockade but not by calcium channel antagonism. J. Am Soc Nephrol 1998, 9:1948-1955.
53. Benediktsson H, Chea R, Davidoff A, Paul LC: Antihypertensive drug treatment in chronic renal allograft rejection in the rat. Effect on structure and function. Transplantation 1996, 62:1634-1642.
54. Lin J, Valeri AM, Markowitz GS, et al.: Angiotensin converting enzyme inhibition in chronic allograft nephropathy. Transplantation 2002, 73:783-788.
55. Philipp T, Legendre C, Geiger H, et al.: Study on the Evaluation of Candesartan cilexetil after Renal Transplantation (SECRET-Study) [abstract]. Available at: http://www.egms.de/en/meetings/hoch2004/ 04hoch126.shtml. Accessed July 26, 2007.